NASDAQ:SRPT实时 99.98-3.34-3.24%2025-03-10 16:00:00 今开:101.84 昨收:103.03 今日区间:98.82-102.14 52周区间:78.67-173.25 成交量:163.92万 成交额:16380.93万 市值:96.88亿 市盈率:77.35 贝塔系数: 每股收益:1.2926 盘后99.980.290.29%成交量30.28万2025-03-10 18:29...
Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript 4 days ago • The Motley Fool Stocks SAREPTA THERAPEUTICS Earnings Results: $SRPT Reports Quarterly Earnings 4 days ago • Quiver Quantitative Stocks Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates 4 days ago • Zacks...
SRPT $106.75 +3.69 +3.58% Add a symbol to your watchlist Most Active
Trending Tickers Above average volume. SRPT $78.33 -22.71% -23.02 NIU $3.91 11.25% 0.40 MUFG $14.29 3.10% 0.43 HUYA $3.72 -18.06% -0.82 Access Premium Tools Search Clear Search Advanced Search Search Results Symbols Loading... Private Companies Loading... Recently Viewed Tickers All...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 E
Trending Tickers Above average volume. SRPT $78.33 -22.71% -23.02 NIU $3.91 11.25% 0.40 MUFG $14.29 3.10% 0.43 HUYA $3.72 -18.06% -0.82 Access Premium Tools Search Clear Search Advanced Search Search Results Symbols Loading... Private Companies Loading... Recently Viewed Tickers All...
CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) --Sarepta Therapeutics, Inc.(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Feb. 26, 2021 that were previously approved by the Compensation Committee of its Board of ...
scottrades: Some Earnings after the close today: $AMD $F $SBUX $ET $SMCI $LTHM $CZR $PAYC $LUMN $MTCH $SPG $CLX $CHK $OKE $YUMC $WU $PRTS $DVAX $TRVG $SAR $PRU $ARWR $BAND $NRDS $SRPT $CWH $OHI $PACB $DENN $BGFV $MUSA $EQX $HLF $INSP $SPT $ANDE $APLE $WELL...
The requests Sarepta Therapeutics (NASDAQ:SRPT) has gotten from the FDA represent a sign of FDA seriousness towards bringing the firm’s drug eteplirsen for...
Roche has a collaboration agreement withSarepta TherapeuticsSRPTfor Elevidys, whereby it is responsible to commercialize Elevidys outside the United States. Last week, Sarepta announced that the FDA has converted the accelerated approval granted to Elevidys to a traditional approval and expanded the...